# Pediatric Sarcoma Essentials — GCMD Library living collection

Updated: n/a · 42 episodes · 302 cited statements

## Episodes
### Clinical Updates & Overviews
- [Clinical & Research Update: Sarcoma w/ Drs. Roshni Dasgupta, Joseph Pressey, Arthur Meyer, Luke Pater](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017) — video · 1:06:24 · [machine version](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017.md)
- [Pediatric Ewing Sarcoma Chemotherapy: What's Actually Changed Since the 1990s? w/ Dr. Joseph Pressey](https://library.globalcastmd.com/watch/pediatric-ewing-sarcoma-chemotherapy-what-s-actually-changed-since-the-1990s-w-d-16618) — video · 0:21 · [machine version](https://library.globalcastmd.com/watch/pediatric-ewing-sarcoma-chemotherapy-what-s-actually-changed-since-the-1990s-w-d-16618.md)
- [The Challenges of Cancer Therapy in Adolescents and Young Adults](https://library.globalcastmd.com/article/the-challenges-of-cancer-therapy-in-adolescents-and-young-adults-17053) — article · [machine version](https://library.globalcastmd.com/article/the-challenges-of-cancer-therapy-in-adolescents-and-young-adults-17053.md)
- [Challenges in the Treatment of Sarcomas of Adolescents and Young Adults](https://library.globalcastmd.com/article/challenges-in-the-treatment-of-sarcomas-of-adolescents-and-young-adults-16994) — article · [machine version](https://library.globalcastmd.com/article/challenges-in-the-treatment-of-sarcomas-of-adolescents-and-young-adults-16994.md)
- [Current concepts on the surgical and medical management of osteosarcoma.](https://library.globalcastmd.com/article/current-concepts-on-the-surgical-and-medical-management-of-osteosarcoma-17048) — article · [machine version](https://library.globalcastmd.com/article/current-concepts-on-the-surgical-and-medical-management-of-osteosarcoma-17048.md)

### Rhabdomyosarcoma
- [Molecular pathogenesis of rhabdomyosarcoma](https://library.globalcastmd.com/article/molecular-pathogenesis-of-rhabdomyosarcoma-17038) — article · [machine version](https://library.globalcastmd.com/article/molecular-pathogenesis-of-rhabdomyosarcoma-17038.md)
- [2D-difference gel electrophoretic proteomic analysis of a cell culture model of alveolar rhabdomyosarcoma](https://library.globalcastmd.com/article/2d-difference-gel-electrophoretic-proteomic-analysis-of-a-cell-culture-model-of-17037) — article · [machine version](https://library.globalcastmd.com/article/2d-difference-gel-electrophoretic-proteomic-analysis-of-a-cell-culture-model-of-17037.md)
- [FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma](https://library.globalcastmd.com/article/foxf1-is-required-for-the-oncogenic-properties-of-pax3-foxo1-in-rhabdomyosarcoma-17015) — article · [machine version](https://library.globalcastmd.com/article/foxf1-is-required-for-the-oncogenic-properties-of-pax3-foxo1-in-rhabdomyosarcoma-17015.md)
- [Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group](https://library.globalcastmd.com/article/hedgehog-pathway-activity-in-pediatric-embryonal-rhabdomyosarcoma-and-undifferen-16997) — article · [machine version](https://library.globalcastmd.com/article/hedgehog-pathway-activity-in-pediatric-embryonal-rhabdomyosarcoma-and-undifferen-16997.md)
- [GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis](https://library.globalcastmd.com/article/gli-inhibitor-gant-61-diminishes-embryonal-and-alveolar-rhabdomyosarcoma-growth-17040) — article · [machine version](https://library.globalcastmd.com/article/gli-inhibitor-gant-61-diminishes-embryonal-and-alveolar-rhabdomyosarcoma-growth-17040.md)
- [Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model](https://library.globalcastmd.com/article/rapamycin-targeting-mtor-and-hedgehog-signaling-pathways-blocks-human-rhabdomyos-17041) — article · [machine version](https://library.globalcastmd.com/article/rapamycin-targeting-mtor-and-hedgehog-signaling-pathways-blocks-human-rhabdomyos-17041.md)
- [Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study](https://library.globalcastmd.com/article/pediatric-anaplastic-embryonal-rhabdomyosarcoma-targeted-therapy-guided-by-genet-16992) — article · [machine version](https://library.globalcastmd.com/article/pediatric-anaplastic-embryonal-rhabdomyosarcoma-targeted-therapy-guided-by-genet-16992.md)
- [Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis](https://library.globalcastmd.com/article/targeting-wild-type-and-mutant-p53-with-small-molecule-cp-31398-blocks-the-growt-17044) — article · [machine version](https://library.globalcastmd.com/article/targeting-wild-type-and-mutant-p53-with-small-molecule-cp-31398-blocks-the-growt-17044.md)
- [CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.](https://library.globalcastmd.com/article/cd133-marks-a-myogenically-primitive-subpopulation-in-rhabdomyosarcoma-cell-line-17043) — article · [machine version](https://library.globalcastmd.com/article/cd133-marks-a-myogenically-primitive-subpopulation-in-rhabdomyosarcoma-cell-line-17043.md)
- [Sentinel lymph node biopsy in head and neck rhabdomyosarcoma](https://library.globalcastmd.com/article/sentinel-lymph-node-biopsy-in-head-and-neck-rhabdomyosarcoma-16991) — article · [machine version](https://library.globalcastmd.com/article/sentinel-lymph-node-biopsy-in-head-and-neck-rhabdomyosarcoma-16991.md)

### Ewing Sarcoma
- [Chemotherapy-induced thrombocytopenia in Ewing sarcoma: Implications and potential for romiplostim supportive care](https://library.globalcastmd.com/article/chemotherapy-induced-thrombocytopenia-in-ewing-sarcoma-implications-and-potentia-17011) — article · [machine version](https://library.globalcastmd.com/article/chemotherapy-induced-thrombocytopenia-in-ewing-sarcoma-implications-and-potentia-17011.md)
- [Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung](https://library.globalcastmd.com/article/results-of-a-randomized-double-blinded-placebo-controlled-phase-2-5-study-of-sar-17021) — article · [machine version](https://library.globalcastmd.com/article/results-of-a-randomized-double-blinded-placebo-controlled-phase-2-5-study-of-sar-17021.md)
- [Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition](https://library.globalcastmd.com/article/molecularly-defined-subsets-of-ewing-sarcoma-tumors-differ-in-their-responses-to-17008) — article · [machine version](https://library.globalcastmd.com/article/molecularly-defined-subsets-of-ewing-sarcoma-tumors-differ-in-their-responses-to-17008.md)
- [Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis](https://library.globalcastmd.com/article/targeting-eya3-in-ewing-sarcoma-retards-tumor-growth-and-angiogenesis-17014) — article · [machine version](https://library.globalcastmd.com/article/targeting-eya3-in-ewing-sarcoma-retards-tumor-growth-and-angiogenesis-17014.md)
- [Primary Ewing sarcoma of the brain: a case report and literature review](https://library.globalcastmd.com/article/primary-ewing-sarcoma-of-the-brain-a-case-report-and-literature-review-17050) — article · [machine version](https://library.globalcastmd.com/article/primary-ewing-sarcoma-of-the-brain-a-case-report-and-literature-review-17050.md)

### Osteosarcoma
- [Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients.](https://library.globalcastmd.com/article/zoledronic-acid-in-metastatic-osteosarcoma-encouraging-progression-free-survival-17030) — article · [machine version](https://library.globalcastmd.com/article/zoledronic-acid-in-metastatic-osteosarcoma-encouraging-progression-free-survival-17030.md)
- [Dramatic multifocal osteosarcoma treatment response in the setting of POT1 tumor predisposition syndrome](https://library.globalcastmd.com/article/dramatic-multifocal-osteosarcoma-treatment-response-in-the-setting-of-pot1-tumor-17001) — article · [machine version](https://library.globalcastmd.com/article/dramatic-multifocal-osteosarcoma-treatment-response-in-the-setting-of-pot1-tumor-17001.md)
- [Genome-Driven Therapy for Chemotherapy-Resistant Metastatic CDK6-Amplified Osteosarcoma](https://library.globalcastmd.com/article/genome-driven-therapy-for-chemotherapy-resistant-metastatic-cdk6-amplified-osteo-17016) — article · [machine version](https://library.globalcastmd.com/article/genome-driven-therapy-for-chemotherapy-resistant-metastatic-cdk6-amplified-osteo-17016.md)

### Malignant Peripheral Nerve Sheath Tumors
- [Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)](https://library.globalcastmd.com/article/targeting-sporadic-and-neurofibromatosis-type-1-related-refractory-malignant-per-17023) — article · [machine version](https://library.globalcastmd.com/article/targeting-sporadic-and-neurofibromatosis-type-1-related-refractory-malignant-per-17023.md)
- [Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.](https://library.globalcastmd.com/article/malignant-peripheral-nerve-sheath-tumor-development-during-mek-inhibitor-treatme-16999) — article · [machine version](https://library.globalcastmd.com/article/malignant-peripheral-nerve-sheath-tumor-development-during-mek-inhibitor-treatme-16999.md)
- [Malignant peripheral nerve sheath tumor: Transformation in a patient with neurofibromatosis type 2](https://library.globalcastmd.com/article/malignant-peripheral-nerve-sheath-tumor-transformation-in-a-patient-with-neurofi-16770) — article · [machine version](https://library.globalcastmd.com/article/malignant-peripheral-nerve-sheath-tumor-transformation-in-a-patient-with-neurofi-16770.md)
- [Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.](https://library.globalcastmd.com/article/targeted-inhibition-of-the-dual-specificity-phosphatases-dusp1-and-dusp6-suppres-17024) — article · [machine version](https://library.globalcastmd.com/article/targeted-inhibition-of-the-dual-specificity-phosphatases-dusp1-and-dusp6-suppres-17024.md)

### Other Soft Tissue Sarcomas
- [Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study](https://library.globalcastmd.com/article/tazemetostat-in-advanced-epithelioid-sarcoma-with-loss-of-ini1-smarcb1-an-intern-17017) — article · [machine version](https://library.globalcastmd.com/article/tazemetostat-in-advanced-epithelioid-sarcoma-with-loss-of-ini1-smarcb1-an-intern-17017.md)
- [Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations](https://library.globalcastmd.com/article/strategies-for-the-treatment-of-infantile-soft-tissue-sarcomas-with-bcor-alterat-17007) — article · [machine version](https://library.globalcastmd.com/article/strategies-for-the-treatment-of-infantile-soft-tissue-sarcomas-with-bcor-alterat-17007.md)
- [Successful Treatment of Recurrent Primitive Myxoid Mesenchymal Tumor of Infancy With BCOR Internal Tandem Duplication](https://library.globalcastmd.com/article/successful-treatment-of-recurrent-primitive-myxoid-mesenchymal-tumor-of-infancy-17027) — article · [machine version](https://library.globalcastmd.com/article/successful-treatment-of-recurrent-primitive-myxoid-mesenchymal-tumor-of-infancy-17027.md)
- [Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis](https://library.globalcastmd.com/article/clinicopathologic-features-of-a-series-of-primary-renal-cic-rearranged-sarcomas-17025) — article · [machine version](https://library.globalcastmd.com/article/clinicopathologic-features-of-a-series-of-primary-renal-cic-rearranged-sarcomas-17025.md)
- [Novel ARHGAP23-FER fusion in a metastatic spindle cell-predominant neoplasm with a myofibroblastic phenotype and a sustained metabolic response to lorlatinib](https://library.globalcastmd.com/article/novel-arhgap23-fer-fusion-in-a-metastatic-spindle-cell-predominant-neoplasm-with-17012) — article · [machine version](https://library.globalcastmd.com/article/novel-arhgap23-fer-fusion-in-a-metastatic-spindle-cell-predominant-neoplasm-with-17012.md)
- [A case of submandibular desmoplastic small round cell tumor: Diagnostic and management approaches to an atypical presentation of a rare tumor](https://library.globalcastmd.com/article/a-case-of-submandibular-desmoplastic-small-round-cell-tumor-diagnostic-and-manag-17022) — article · [machine version](https://library.globalcastmd.com/article/a-case-of-submandibular-desmoplastic-small-round-cell-tumor-diagnostic-and-manag-17022.md)

### Diagnostic Approaches
- [Pediatric and Young Adult Image-Guided Percutaneous Bone Biopsy-A New Standard of Care?](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545) — video · 1:05 · [machine version](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545.md)
- [ASO Author Reflections: Minimizing Time in Hospital via Bone Biopsy or Other Means](https://library.globalcastmd.com/article/aso-author-reflections-minimizing-time-in-hospital-via-bone-biopsy-or-other-mean-17006) — article · [machine version](https://library.globalcastmd.com/article/aso-author-reflections-minimizing-time-in-hospital-via-bone-biopsy-or-other-mean-17006.md)
- [Fluorescent-guided surgery and the use of indocyanine green sentinel lymph node mapping in the pediatric and young adult oncology population](https://library.globalcastmd.com/article/fluorescent-guided-surgery-and-the-use-of-indocyanine-green-sentinel-lymph-node-16983) — article · [machine version](https://library.globalcastmd.com/article/fluorescent-guided-surgery-and-the-use-of-indocyanine-green-sentinel-lymph-node-16983.md)
- [Detection of lymph node metastases in pediatric and adolescent/young adult sarcoma: Sentinel lymph node biopsy versus fludeoxyglucose positron emission tomography imaging-A prospective trial](https://library.globalcastmd.com/article/detection-of-lymph-node-metastases-in-pediatric-and-adolescent-young-adult-sarco-16996) — article · [machine version](https://library.globalcastmd.com/article/detection-of-lymph-node-metastases-in-pediatric-and-adolescent-young-adult-sarco-16996.md)
- [MR Imaging of Pediatric Musculoskeletal Tumors:: Recent Advances and Clinical Applications.](https://library.globalcastmd.com/article/mr-imaging-of-pediatric-musculoskeletal-tumors-recent-advances-and-clinical-appl-16989) — article · [machine version](https://library.globalcastmd.com/article/mr-imaging-of-pediatric-musculoskeletal-tumors-recent-advances-and-clinical-appl-16989.md)
- [Comparison of 0.3-mSv CT to Standard-Dose CT for Detection of Lung Nodules in Children and Young Adults With Cancer.](https://library.globalcastmd.com/article/comparison-of-0-3-msv-ct-to-standard-dose-ct-for-detection-of-lung-nodules-in-ch-17013) — article · [machine version](https://library.globalcastmd.com/article/comparison-of-0-3-msv-ct-to-standard-dose-ct-for-detection-of-lung-nodules-in-ch-17013.md)

### Genomic & Molecular Analysis
- [Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors](https://library.globalcastmd.com/article/whole-exome-sequencing-identified-sixty-five-coding-mutations-in-four-neuroblast-16993) — article · [machine version](https://library.globalcastmd.com/article/whole-exome-sequencing-identified-sixty-five-coding-mutations-in-four-neuroblast-16993.md)
- [Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes](https://library.globalcastmd.com/article/real-time-genomic-profiling-of-histiocytoses-identifies-early-kinase-domain-braf-17029) — article · [machine version](https://library.globalcastmd.com/article/real-time-genomic-profiling-of-histiocytoses-identifies-early-kinase-domain-braf-17029.md)
- [Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).](https://library.globalcastmd.com/article/using-cancer-phenotype-sex-specificity-to-enable-unbiased-penetrance-estimation-17003) — article · [machine version](https://library.globalcastmd.com/article/using-cancer-phenotype-sex-specificity-to-enable-unbiased-penetrance-estimation-17003.md)

## Chapters
- [0:00](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545?t=0) Image-Guided Percutaneous Biopsy for Pediatric Bone Tumors (Ep 34)
- [4:13](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=253) Case 1 Introduction: 10-Year-Old with Chest Wall Ewing Sarcoma - Presentation and Imaging (Ep 1)
- [10:05](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=605) Case 1: Neoadjuvant Chemotherapy and Surgical Planning (Ep 1)
- [14:40](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=880) Case 1: Radiation Therapy and Completion of Treatment (Ep 1)
- [21:40](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1300) Case 2 Introduction: 12-Month-Old with Ovarian Mass - Presentation and Diagnosis (Ep 1)
- [25:53](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1553) Case 2: SCCOHT Biology, Staging, and Induction Chemotherapy (Ep 1)
- [36:06](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2166) Case 2: Second-Look Surgery with HIPEC and Consolidation (Ep 1)
- [45:28](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2728) Case 2: Germline SMARCA4, Radiation Decision, and Long-Term Outcomes (Ep 1)
- [51:36](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3096) Case 3 Introduction: 2-Year-Old with Chest Wall Rhabdomyosarcoma - Presentation and Surgical Approach (Ep 1)
- [58:42](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3522) Case 3: Radiation Decision and Li-Fraumeni Considerations (Ep 1)
- [60:46](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3646) Multidisciplinary Discussion: Germline Testing and Individualized Care (Ep 1)

## Statements
Every statement is attributed, typed, and timestamped; the link is the citation.
- The study evaluated 169 biopsies in 141 patients over a 10-year period at a single institution. — Sophia Schermerhorn (clinical) [Ep 34 · 0:13](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545?t=13)
- Nearly 90% of the biopsies were core-needle biopsies. — Sophia Schermerhorn (clinical) [Ep 34 · 0:19](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545?t=19)
- All biopsies were performed with image guidance, most commonly CT, sometimes combined with fluoroscopy and ultrasound. — Sophia Schermerhorn (clinical) [Ep 34 · 0:22](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545?t=22)
- All biopsies were performed by interventional radiologists. — Sophia Schermerhorn (clinical) [Ep 34 · 0:28](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545?t=28)
- 97.9% of biopsies were diagnostic. — Sophia Schermerhorn (clinical) [Ep 34 · 0:33](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545?t=33)
- Only 3 patients required repeat biopsy. — Sophia Schermerhorn (clinical) [Ep 34 · 0:33](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545?t=33)
- There was one patient with transient sciatic nerve paresis, which resolved. — Sophia Schermerhorn (clinical) [Ep 34 · 0:40](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545?t=40)
- The complication rate was 0.7%. — Sophia Schermerhorn (clinical) [Ep 34 · 0:43](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545?t=43)
- The approach provided sufficient tissue for histology, immunostains, and molecular studies. — Sophia Schermerhorn (clinical) [Ep 34 · 0:46](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545?t=46)
- Immunostains and molecular studies are increasingly essential for modern risk stratification and targeted therapy. — Sophia Schermerhorn (clinical) [Ep 34 · 0:46](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545?t=46)
- Image-guided percutaneous biopsy should be strongly considered the diagnostic modality of choice for pediatric bone and soft tissue tumors. — Sophia Schermerhorn (opinion) [Ep 34 · 0:56](https://library.globalcastmd.com/watch/pediatric-and-young-adult-image-guided-percutaneous-bone-biopsy-a-new-standard-o-11545?t=56)
- Compressed-interval VDC/IE chemotherapy given every 2 weeks is now well proven to be of benefit over 3-week schedule for Ewing sarcoma — Joseph Pressey (clinical) [Ep 1 · 9:23](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=563)
- For chest wall sarcomas, the old adage of needing a rib above and a rib below for margins is not the case anymore; the goal is just to get negative margins if possible — Roshni Dasgupta (clinical) [Ep 1 · 11:23](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=683)
- When tumor is adherent to diaphragm or pericardium, you should not dissect these structures off the tumor because you don't know where the margin is; instead take a portion of the adherent structure with the tumor — Roshni Dasgupta (clinical) [Ep 1 · 12:18](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=738)
- Titanium rib reconstruction systems may need revision as the child grows, particularly during puberty with significant growth spurts — Roshni Dasgupta (clinical) [Ep 1 · 14:05](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=845)
- For Ewing sarcoma radiotherapy, treatment typically involves two phases: disease presentation volume and then more specific targeting of gross disease or positive margins — Luke Pater (clinical) [Ep 1 · 15:29](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=929)
- Protons are preferred over photons for focused boost volumes because they reduce low-dose exposure to non-target tissue beyond the target, though in lungs the benefit is compromised due to low-density tissue causing scatter — Luke Pater (clinical) [Ep 1 · 20:12](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1212)
- Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) was originally described around 1980 in young adult women presenting with ovarian tumors with nondescript morphology, often associated with hypercalcemia — Joseph Pressey (epidemiological) [Ep 1 · 23:23](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1403)
- SCCOHT tumors are actually malignant rhabdoid tumors; some have postulated they should be called malignant rhabdoid tumor of the ovary — Joseph Pressey (clinical) [Ep 1 · 23:47](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1427)
- In 2014, three labs simultaneously identified SMARCA4 mutation (usually single nucleotide variant) as the underlying genetic defect in SCCOHT — Joseph Pressey (clinical) [Ep 1 · 24:06](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1446)
- SMARCA4 encodes BRG1 and its loss unifies all SCCOHT tumors; like Ewing sarcoma, these tumors have very low tumor mutational burden with SMARCA4 usually the only mutation found — Joseph Pressey (clinical) [Ep 1 · 24:40](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1480)
- Many SCCOHT patients enter the OR without this diagnosis in the differential; they are usually thought to be germ cell tumors, resulting in incomplete initial surgery — Joseph Pressey (clinical) [Ep 1 · 26:39](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1599)
- SCCOHT is a chemo-sensitive tumor but only transiently so; it is very important to start intensive systemic chemotherapy quickly rather than sending patients back for immediate second-look operation — Joseph Pressey (clinical) [Ep 1 · 27:00](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1620)
- The VPCBAE regimen (vinorelbine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, etoposide) with all six agents given every 21-day cycle is very intensive toxic therapy requiring meticulous supportive care — Joseph Pressey (clinical) [Ep 1 · 27:20](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1640)
- Four cycles of VPCBAE induction chemotherapy are given prior to second-look operation for SCCOHT; patients with measurable disease after initial surgery often respond well even by RECIST criteria — Joseph Pressey (clinical) [Ep 1 · 27:43](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1663)
- The 12-month-old SCCOHT patient is the youngest ever described with this tumor; the average age for diagnosis is 24 years — Joseph Pressey (epidemiological) [Ep 1 · 28:25](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1705)
- MRIs and PET scans are not great for detecting peritoneal disease and very small nodules (1mm); second-look surgery is necessary to identify disease that imaging cannot detect — Roshni Dasgupta (clinical) [Ep 1 · 29:18](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1758)
- For SCCOHT second-look surgery, laparoscopy is used initially to understand extent of disease and determine size of laparotomy incision needed; the operation is never done with laparoscopy alone — Roshni Dasgupta (clinical) [Ep 1 · 29:44](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1784)
- Complete cytoreduction for SCCOHT includes removing all visible disease, with particular attention to peritoneal reflection in pouch of Douglas and surface of rectum where tumor can hide after spill — Roshni Dasgupta (clinical) [Ep 1 · 30:40](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1840)
- HIPEC in pediatric patients requires a multidisciplinary team experienced in this procedure; it is not the same as adult HIPEC — Roshni Dasgupta (clinical) [Ep 1 · 32:25](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1945)
- HIPEC protocol includes preoperative hyperhydration (1-2x maintenance fluids), warming abdomen to 42°C, cisplatin given in 2/3 dose initially and 1/3 at 45 minutes, continuous shaking for 90-minute dwell time, sodium thiosulfate infusion at 30 minutes to scavenge cisplatin, and 4-5L washout — Roshni Dasgupta (clinical) [Ep 1 · 32:59](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=1979)
- Post-HIPEC patients receive 24 hours of hyperhydration in ICU; main counseled toxicities are ileus and kidney function issues, though the Cincinnati protocol has not seen significant renal toxicity — Roshni Dasgupta (clinical) [Ep 1 · 34:49](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2089)
- SCCOHT patients can resume next cycle of chemotherapy 4-7 days postoperatively after HIPEC once bowel function recovers — Roshni Dasgupta (clinical) [Ep 1 · 35:50](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2150)
- Maintaining interval compression as dense as possible (7-8 days to resume chemotherapy post-HIPEC) is very important to continue killing residual tumor cells — Joseph Pressey (clinical) [Ep 1 · 36:06](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2166)
- SCCOHT treatment uses 6 cycles of VPCBAE (usually 4 induction, 2 adjuvant); some stage 1 patients or those with considerable toxicity (especially renal) have stopped after 5 cycles to get to transplant in good health — Joseph Pressey (clinical) [Ep 1 · 36:39](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2199)
- Cincinnati uses busulfan-thiotepa conditioning for autologous stem cell transplant in SCCOHT, which is more toxic than the carboplatin-based regimen used by the French consortium but complements VPCBAE better with heavy alkylator exposure — Joseph Pressey (clinical) [Ep 1 · 37:08](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2228)
- Approximately 43% of SCCOHT patients carry germline SMARCA4 mutations; in Cincinnati's last 20 patients, 8 had germline SMARCA4 (40%) — Joseph Pressey (epidemiological) [Ep 1 · 37:56](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2276)
- For SCCOHT patients with germline SMARCA4, contralateral salpingo-oophorectomy should be performed at second-look operation because it would be nearly impossible to treat a metachronous SCCOHT tumor a second time with intensive therapy — Joseph Pressey (clinical) [Ep 1 · 38:21](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2301)
- Germline SMARCA4 mutations have been found in older SCCOHT patients in their late 30s with no prior personal or family history of cancer; all patients should be tested regardless of family history — Joseph Pressey (clinical) [Ep 1 · 38:55](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2335)
- Hysterectomy should be considered for germline SMARCA4 carriers due to risk of SMARCA4-deficient uterine sarcoma, which peaks around age 50 (later than SCCOHT which peaks at 23-24 years) — Joseph Pressey (clinical) [Ep 1 · 39:16](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2356)
- Two patients who survived SCCOHT developed metachronous SCCOHT tumors in the contralateral ovary and subsequently died, demonstrating this is a real risk not worth taking — Joseph Pressey (clinical) [Ep 1 · 39:37](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2377)
- Penetrance of germline SMARCA4 is estimated at 62% based on UK Biobank study comparing males vs females over age 40, assuming the deficit of females was explained by SCCOHT deaths — Joseph Pressey (epidemiological) [Ep 1 · 40:10](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2410)
- Cincinnati's methodology estimates SMARCA4 penetrance closer to 20% studying family members of SCCOHT patients; even at 20% this is considered considerable risk for otherwise healthy female carriers — Joseph Pressey (epidemiological) [Ep 1 · 41:08](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2468)
- About 20% of SCCOHT patients have de novo SMARCA4 mutations with neither parent carrying the mutation — Joseph Pressey (epidemiological) [Ep 1 · 41:35](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2495)
- Major long-term toxicity from SCCOHT treatment is ototoxicity requiring hearing aids; otherwise patients grow and develop well — Joseph Pressey (clinical) [Ep 1 · 42:11](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2531)
- Whole abdomen radiation for SCCOHT was used historically but is excessively toxic in patients who receive autologous stem cell transplant and HIPEC; Cincinnati has walked away from this approach — Luke Pater (clinical) [Ep 1 · 43:16](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2596)
- Whole abdomen radiation could still be considered for SCCOHT patients who do not get HIPEC or autologous bone marrow transplant — Luke Pater (opinion) [Ep 1 · 43:46](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2626)
- Protons are ideal for SCCOHT lymph node radiation to minimize bowel, liver, kidney exposure and in similar scenarios to minimize dose to uterus, ovaries, pancreas, and spleen (low-dose pancreatic/splenic exposure is problematic long-term for metabolic syndrome and immune function) — Luke Pater (clinical) [Ep 1 · 44:30](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=2670)
- Cincinnati's SCCOHT series of 20 consecutive patients (2018-2024) with median follow-up of 58 months shows 60% overall survival, about 20 percentage points higher than the French study published in 2020 — Joseph Pressey (epidemiological) [Ep 1 · 50:21](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3021)
- For rhabdomyosarcoma, surgery should only be attempted if negative margins are achievable; if only debulking is possible, local control should be done with radiation only — Roshni Dasgupta (clinical) [Ep 1 · 55:18](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3318)
- The goal of delayed primary excision (DPE) for rhabdomyosarcoma is to achieve at least R1 disease (microscopic residual only) — Roshni Dasgupta (clinical) [Ep 1 · 55:41](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3341)
- Scapular disarticulation provides excellent access for high chest wall tumors, allowing the chest to be opened like a book — Roshni Dasgupta (clinical) [Ep 1 · 56:33](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3393)
- For tumors near subclavian vessels and brachial plexus, a neck incision (similar to first rib operation for thoracic outlet syndrome) allows isolation of these structures from above before thoracotomy — Roshni Dasgupta (clinical) [Ep 1 · 56:47](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3407)
- For high chest wall defects covered by scapula, bony reconstruction is not needed; Gore-Tex mesh with trapezius flap rotation provides adequate coverage — Roshni Dasgupta (clinical) [Ep 1 · 57:34](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3454)
- After delayed primary excision for presenting R3/group 3 rhabdomyosarcoma, radiotherapy is typically recommended — Luke Pater (clinical) [Ep 1 · 59:48](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3588)
- In the rhabdomyosarcoma case with germline TP53 mutation, radiation was deferred due to the mutation combined with excellent chemotherapy response and complete surgical resection, despite this being non-standard for group 3 disease — Luke Pater (clinical) [Ep 1 · 60:13](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3613)
- Radiation-induced sarcomas in Li-Fraumeni patients are typically more aggressive and less chemosensitive than primary sarcomas — Joseph Pressey (clinical) [Ep 1 · 60:53](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3653)
- The incidence of secondary malignancy from radiation is assumed to be higher the younger the patient, both because of more years to develop it and an inherent increased risk with young age — Luke Pater (clinical) [Ep 1 · 61:31](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3691)
- Radiation decisions in young children involve nuanced discussions of toxicities including pulmonary function, cardiac exposure, wound healing, and chest wall development, individualized case by case — Luke Pater (opinion) [Ep 1 · 61:48](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3708)
- The risk of hereditary predisposition among all sarcoma patients may be as high as 15% — Joseph Pressey (epidemiological) [Ep 1 · 64:17](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3857)
- Cincinnati now performs universal germline testing for all newly diagnosed solid tumor patients and many benign tumors like desmoid tumors (with FAP testing) — Joseph Pressey (clinical) [Ep 1 · 64:27](https://library.globalcastmd.com/watch/clinical-research-update-sarcoma-w-drs-roshni-dasgupta-joseph-pressey-arthur-mey-14017?t=3867)
- Malignant peripheral nerve sheath tumor is a rare soft-tissue sarcoma with an unfavorable prognosis and limited therapeutic options. (established) (no timestamp yet)
- MPNSTs are often associated with neurofibromatosis type 1 and usually arise from preexisting neurofibromas. (established) (no timestamp yet)
- MPNSTs in patients with neurofibromatosis type 2 have been reported in only exceedingly rare cases. (established) (no timestamp yet)
- The mechanisms underlying transformation of peripheral nerve sheath tumors into MPNSTs in neurofibromatosis type 2 have not been fully elucidated. (open) (no timestamp yet)
- Technetium-99m lymphoscintigraphy with blue dye injection is an accepted method for sentinel lymph node mapping. (established) (no timestamp yet)
- Blue dye has known adverse effects in sentinel lymph node mapping procedures. (established) (no timestamp yet)
- Injection of technetium-99m may increase time under anesthesia for pediatric patients. (established) (no timestamp yet)
- Thirty patients underwent 36 procedures with 96 total specimens for sentinel lymph node biopsy. (research) (no timestamp yet)
- Patients received preoperative intradermal injection of technetium-99m, followed by intradermal injection of isosulfan blue and indocyanine green. (research) (no timestamp yet)
- Indocyanine green had a sensitivity of 87% and positive predictive value of 83% for detection of technetium-99m-hot lymph nodes. (research) (no timestamp yet)
- Blue dye had a sensitivity of 44% and positive predictive value of 97% for detection of technetium-99m-hot lymph nodes. (research) (no timestamp yet)
- For detection of pathologically confirmed lymph nodes, indocyanine green had a sensitivity of 84% and a positive predictive value of 91%. (research) (no timestamp yet)
- Technetium-99m had a sensitivity of 82% and a positive predictive value of 94% for detection of pathologically confirmed lymph nodes. (research) (no timestamp yet)
- Indocyanine green had no significant difference in odds of being positive in pathology-confirmed lymph nodes compared to technetium-99m (odds ratio 0.818, 95% confidence interval 0.3-2.172, p = 0.823). (research) (no timestamp yet)
- Indocyanine green had higher odds of detecting pathology-confirmed lymph nodes than isosulfan blue (odds ratio 0.025, 95% confidence interval 0.001-0.148, p < 0.001). (research) (no timestamp yet)
- Indocyanine green is efficacious as an adjunct to sentinel lymph node biopsy in the pediatric and young adult population. (research) (no timestamp yet)
- Pediatric musculoskeletal tumors comprise approximately 10% of childhood neoplasms. (established) (no timestamp yet)
- MR imaging is the imaging evaluation standard for pediatric musculoskeletal tumors. (established) (no timestamp yet)
- MR imaging is used to identify tumor origin in pediatric musculoskeletal tumors. (recommendation) (no timestamp yet)
- MR imaging is used for tissue characterization of pediatric musculoskeletal tumors. (recommendation) (no timestamp yet)
- MR imaging defines tumor extent and relationship to adjacent structures. (recommendation) (no timestamp yet)
- MR imaging is used for therapeutic response assessment in posttreatment surveillance of pediatric musculoskeletal tumors. (recommendation) (no timestamp yet)
- Head and neck rhabdomyosarcoma lymph node staging is challenging due to varied patterns of lymphatic drainage and the suboptimal predictive value of available imaging modalities. (established) (no timestamp yet)
- Regional relapse rates in head and neck rhabdomyosarcoma are unacceptably high. (established) (no timestamp yet)
- Sentinel lymph node biopsy is safe and feasible in pediatric patients with head and neck rhabdomyosarcoma. (research) (no timestamp yet)
- Pathologic findings from sentinel lymph node biopsy led to intensification of regional and/or systemic therapy in two of six patients. (research) (no timestamp yet)
- Therapy for rhabdomyosarcoma has generally been limited to combinations of conventional cytotoxic agents similar to regimens originally developed in the late 1960s. (established) (no timestamp yet)
- Identification of molecular alterations through next-generation sequencing of individual tumor specimens has facilitated the use of more targeted therapeutic approaches for various malignancies. (established) (no timestamp yet)
- Malignancies common in children have been less amenable to targeted therapies. (established) (no timestamp yet)
- Genomic testing of embryonal rhabdomyosarcoma with anaplastic features revealed mutations in BCOR, ARID1A, and SETD2 genes, each of which contributes to epigenetic regulation and interacts with or modifies the activity of histone deacetylases. (research) (no timestamp yet)
- The patient was treated with the HDAC inhibitor vorinostat as a single agent based on genomic findings showing mutations affecting histone deacetylase activity. (research) (no timestamp yet)
- The tumor responded transiently to vorinostat followed by subsequent disease progression. (research) (no timestamp yet)
- The antitumor activity of vorinostat observed with the patient-derived xenograft model reflected clinical observations in that obvious areas of tumor necrosis were evident. (research) (no timestamp yet)
- Neuroblastoma accounts for approximately 15% of childhood deaths from cancer. (established) (no timestamp yet)
- The five-year survival for patients with high-risk stage 4 neuroblastoma has not improved in two decades. (established) (no timestamp yet)
- Whole exome sequencing identified 43 mutations that had not been reported previously among four neuroblastoma tumors. (research) (no timestamp yet)
- One mutation was present in two of the four tumors analyzed. (research) (no timestamp yet)
- Whole exome sequencing corroborated 22 mutations that were reported previously. (research) (no timestamp yet)
- No single mutation occurred in all four tumors or in all stage 4 tumors. (research) (no timestamp yet)
- Three of the four tumors harbored genes with CADD scores ≥20, indicative of mutations associated with human pathologies. (research) (no timestamp yet)
- The average depth of coverage ranged from 39.68 to 90.27, with >99% sequences mapping to the genome. (research) (no timestamp yet)
- The three stage 4 tumors contained mutations in genes encoding protein products that regulate immune function or cell adhesion and tumor cell metastasis. (research) (no timestamp yet)
- Adolescent and young adult sarcoma patients do not fare as well as their younger counterparts. (established) (no timestamp yet)
- Compared to younger patients, AYA patients often develop genetically distinct tumors. (established) (no timestamp yet)
- AYA patients are more likely to suffer characteristic therapy-related toxicities compared to younger patients. (established) (no timestamp yet)
- Lack of clinical trial participation among AYA patients has slowed the establishment of optimized age-specific treatment protocols. (established) (no timestamp yet)
- The relative rarity of sarcomas among adult cancers may limit the familiarity of oncologists with state of the art diagnostic and therapeutic aspects of sarcomas in young adults. (established) (no timestamp yet)
- Improved enrollment on clinical trials is a critical step in addressing the challenges faced by AYA patients. (recommendation) (no timestamp yet)
- Lymph node metastases are an important cause of treatment failure for pediatric and adolescent/young adult sarcoma patients. (established) (no timestamp yet)
- Nodal sampling is recommended for certain sarcoma subtypes that have a predilection for lymphatic spread. (guideline) (no timestamp yet)
- A median of 2.4 sentinel nodes were sampled per patient. (research) (no timestamp yet)
- No wound infections or chronic lymphedema occurred following sentinel lymph node biopsy. (research) (no timestamp yet)
- Sentinel lymph node biopsy identified tumors in 7 of 28 patients (25%). (research) (no timestamp yet)
- Sentinel lymph node biopsy identified nodal metastases in 3 patients who had normal PET-CT imaging of the nodal basin. (research) (no timestamp yet)
- PET-CT demonstrated hypermetabolic regional nodes in 14 patients. (research) (no timestamp yet)
- PET-CT had a positive predictive value of only 29% for detecting nodal metastases. (research) (no timestamp yet)
- Aberrant activation of the hedgehog signaling pathway is implicated widely in both pediatric and adult malignancies. (established) (no timestamp yet)
- Inactivation of the hedgehog regulator PTCH is responsible for the Gorlin cancer predisposition syndrome. (established) (no timestamp yet)
- The spectrum of tumors found in Gorlin Syndrome includes basal cell carcinoma, medulloblastoma, and rarely, rhabdomyosarcoma. (established) (no timestamp yet)
- Expression of GLI1 with or without PTCH was detected in substantial subsets of embryonal rhabdomyosarcoma and undifferentiated sarcoma tumors but only rarely in alveolar rhabdomyosarcoma tumors. (research) (no timestamp yet)
- Neither PTCH mutations nor activating SMO mutations were detected in embryonal rhabdomyosarcoma tumors with high GLI1 expression. (research) (no timestamp yet)
- Microarray analysis demonstrated relative overexpression of downstream hedgehog targets in embryonal rhabdomyosarcoma tumors with high or intermediate GLI1 expression. (research) (no timestamp yet)
- Hedgehog pathway activity in embryonal rhabdomyosarcoma tumors did not correlate with a unique clinical phenotype. (research) (no timestamp yet)
- People with Neurofibromatosis type 1 are at risk of developing benign and malignant peripheral nerve sheath tumors. (established) (no timestamp yet)
- In NF1, the overall lifetime risk of MPNST is estimated at 8%-13%. (established) (no timestamp yet)
- Increased MPNST risk is associated with specific germline mutations and larger benign tumor burden in NF1. (established) (no timestamp yet)
- Selumetinib, a mitogen-activating protein kinase kinase inhibitor, was the first FDA-approved therapy for NF1. (established) (no timestamp yet)
- POT1 tumor predisposition is associated with a spectrum of malignancies due to loss of function mutations in POT1 leading to telomere elongation and genomic instability. (established) (no timestamp yet)
- Osteosarcoma is the most common primary malignant bone tumor and has a poor prognosis when multifocal. (established) (no timestamp yet)
- A POT1 splice site variant (c.949+1G>C) identified both somatically and in the germline is consistent with POT1 tumor predisposition syndrome. (research) (no timestamp yet)
- Multifocal osteosarcoma with POT1 tumor predisposition syndrome displayed marked chemosensitivity to standard of care therapy and long-term remission was achieved. (research) (no timestamp yet)
- Hereditable alterations in telomeric function including POT1 are enriched in sarcoma susceptibility. (established) (no timestamp yet)
- Hereditary tumor predisposition syndromes often increase osteosarcoma risk. (established) (no timestamp yet)
- Five patients with POT1 tumor predisposition syndrome have been reported with osteosarcoma. (research) (no timestamp yet)
- Multifocal osteosarcoma is rare and retrospective cohorts suggest dismal prognosis. (established) (no timestamp yet)
- Synchronous multifocal osteosarcoma exquisitely sensitive to chemotherapy may represent a unique phenotype for POT1 tumor predisposition syndrome. (open) (no timestamp yet)
- Small cell carcinoma of the ovary, hypercalcemic type has a mean age of onset of 24 years. (established) (no timestamp yet)
- Nearly all cases of SCCOHT are associated with somatic or germline pathogenic variants in SMARCA4. (established) (no timestamp yet)
- Early bilateral oophorectomy is recommended for unaffected females with a SMARCA4 germline pathogenic variant. (recommendation) (no timestamp yet)
- The penetrance of SMARCA4 germline pathogenic variants for SCCOHT is highly uncertain. (open) (no timestamp yet)
- BCOR alterations are described in ultra-rare infantile soft tissue sarcomas including primitive myxoid mesenchymal tumor of infancy and undifferentiated round cell sarcoma. (established) (no timestamp yet)
- Nine patients aged 6 weeks to 15 months with BCOR-rearranged soft tissue sarcomas were identified in this multi-institutional retrospective study. (research) (no timestamp yet)
- One tumor carried a BCOR::CCNB3 fusion, whereas 7 tumors harbored internal tandem duplication of BCOR. (research) (no timestamp yet)
- Four patients underwent upfront surgery with residual disease that progressed locally after a median of 2.5 months. (research) (no timestamp yet)
- Locoregional recurrences were observed in hybrid morphology patients, and the undifferentiated round cell sarcoma case recurred with brain metastases. (research) (no timestamp yet)
- Complete radiographic responses after chemotherapy were achieved in patients treated with vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide. (research) (no timestamp yet)
- Complete radiographic responses after chemotherapy were achieved in patients treated with vincristine/doxorubicin/cyclophosphamide alternating with cyclophosphamide/etoposide (regimen I). (research) (no timestamp yet)
- Complete radiographic responses after chemotherapy were achieved in patients treated with ifosfamide/carboplatin/etoposide. (research) (no timestamp yet)
- Seven patients received radiotherapy. (research) (no timestamp yet)
- With a median of 23.5 months off therapy, 8 patients are with no evidence of disease. (research) (no timestamp yet)
- Observation was inadequate for the management of untreated postsurgical residual disease in this cohort. (recommendation) (no timestamp yet)
- Tumors demonstrated chemosensitivity with anthracycline-based regimens. (research) (no timestamp yet)
- Ewing sarcoma tumors fall into two molecularly defined groups based on IGF1R localization, replication stress levels, and drug sensitivity patterns. (research) (no timestamp yet)
- Tumors with predominantly nuclear IGF1R have upregulated DNA damage tolerance pathways, low replication stress, low RRM2B levels, and high levels of WEE1 and RAD21. (research) (no timestamp yet)
- Tumors with nuclear IGF1R are relatively insensitive to IGF1R inhibition. (research) (no timestamp yet)
- Tumors with membrane-associated IGF1R have high replication stress, high RRM2B levels, low levels of WEE1 and RAD21, and are sensitive to IGF1R or WEE1-targeted inhibitors. (research) (no timestamp yet)
- Matched primary and metastatic tumors from the same patient differ in IGF1R localization, levels of replication stress, and inhibitor sensitivity. (research) (no timestamp yet)
- Combined IGF1R and WEE1 inhibition shows activity across both tumor subsets. (research) (no timestamp yet)
- Maintaining dose-dense, interval-compressed chemotherapy improves survival in patients with Ewing sarcoma but is limited by myelosuppression. (established) (no timestamp yet)
- Chemotherapy-induced thrombocytopenia was defined as a failure to achieve 75,000 platelets per microliter by day 21 after the start of any chemotherapy cycle. (guideline) (no timestamp yet)
- Twenty-seven out of 42 patients (64%) developed isolated chemotherapy-induced thrombocytopenia, delaying one to four chemotherapy cycles per patient. (research) (no timestamp yet)
- Chemotherapy-induced thrombocytopenia occurred during consolidation therapy in 24 of 27 patients (88.9%). (research) (no timestamp yet)
- Chemotherapy-induced thrombocytopenia occurred with ifosfamide/etoposide cycles in 24 of 27 patients (88.9%). (research) (no timestamp yet)
- Univariate analysis failed to identify risk factors for chemotherapy-induced thrombocytopenia. (research) (no timestamp yet)
- The use of radiation approached significance as a risk factor for chemotherapy-induced thrombocytopenia (p-value = .056). (research) (no timestamp yet)
- The median starting dose of romiplostim was 3 μg/kg (range 1-5). (research) (no timestamp yet)
- Romiplostim doses were escalated weekly by 1-2 to 4-10 μg/kg and continued throughout chemotherapy. (research) (no timestamp yet)
- A higher romiplostim dose was associated with a higher change in average platelet counts from baseline, r = .73 (p = .04). (research) (no timestamp yet)
- No romiplostim-related adverse events were identified aside from mild headache. (research) (no timestamp yet)
- Chemotherapy-induced thrombocytopenia is the primary reason for the inability to maintain treatment intensity in Ewing sarcoma. (research) (no timestamp yet)
- CT is the imaging modality of choice to identify lung metastasis. (established) (no timestamp yet)
- The study enrolled patients 4-21 years old with known or suspected malignancy who were undergoing clinically indicated chest CT. (research) (no timestamp yet)
- EWSR1/FLI1, the most common fusion gene in Ewing sarcoma, upregulates expression of the Eyes Absent 3 (EYA3) transactivator-phosphatase protein. (established) (no timestamp yet)
- Loss of EYA3 in Ewing sarcoma cells inhibits tumor growth and tumor angiogenesis. (research) (no timestamp yet)
- Pharmacologic inhibition of the EYA3 tyrosine phosphatase activity inhibits tumor growth and tumor angiogenesis. (research) (no timestamp yet)
- EYA3 regulates levels of VEGFA in Ewing tumors. (research) (no timestamp yet)
- EYA3 promotes DNA damage repair and survival of Ewing sarcoma tumor cells. (research) (no timestamp yet)
- Target engagement is demonstrated in tumor tissue through elevated levels of the EYA3 substrate H2AX-pY142 upon loss of EYA3 or with Benzarone treatment. (research) (no timestamp yet)
- The efficacy of EYA3 tyrosine phosphatase inhibition in attenuating tumor growth and angiogenesis is corroborated in an Ewing sarcoma patient-derived tumor xenograft. (research) (no timestamp yet)
- PAX3-FOXO1 fusion protein is the key oncogenic driver in fusion positive rhabdomyosarcoma (FP-RMS), an aggressive soft tissue malignancy with a particularly poor prognosis. (established) (no timestamp yet)
- FOXF1 transcription factor is uniquely expressed in FP-RMS and is required for FP-RMS tumorigenesis. (research) (no timestamp yet)
- PAX3-FOXO1 directly binds to FOXF1 enhancers and induces FOXF1 gene expression. (research) (no timestamp yet)
- CRISPR/Cas9 mediated inactivation of either FOXF1 coding sequence or FOXF1 enhancers suppresses FP-RMS tumorigenesis even in the presence of PAX3-FOXO1 oncogene. (research) (no timestamp yet)
- Knockdown or genetic knockout of FOXF1 induces myogenic differentiation in PAX3-FOXO1-positive FP-RMS. (research) (no timestamp yet)
- Over-expression of FOXF1 decreases myogenic differentiation in primary human myoblasts. (research) (no timestamp yet)
- In FP-RMS tumor cells, FOXF1 protein binds chromatin near enhancers associated with FP-RMS gene signature. (research) (no timestamp yet)
- FOXF1 cooperates with PAX3-FOXO1 and E-box transcription factors MYOD1 and MYOG to regulate FP-RMS-specific gene expression. (research) (no timestamp yet)
- FOXF1 functions downstream of PAX3-FOXO1 to promote FP-RMS tumorigenesis. (research) (no timestamp yet)
- Over 90% of epithelioid sarcomas have lost INI1 expression, leading to oncogenic dependence on the transcriptional repressor EZH2. (established) (no timestamp yet)
- Eligible patients were aged 16 years or older with histologically confirmed, locally advanced or metastatic epithelioid sarcoma. (guideline) (no timestamp yet)
- Patients required documented loss of INI1 expression by immunohistochemical analysis or biallelic SMARCB1 alterations, or both. (guideline) (no timestamp yet)
- Eligible patients had an Eastern Cooperative Oncology Group performance status score of 0-2. (guideline) (no timestamp yet)
- Patients received 800 mg tazemetostat orally twice per day in continuous 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent. (recommendation) (no timestamp yet)
- The primary endpoint was investigator-assessed objective response rate measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1. (guideline) (no timestamp yet)
- A third of osteosarcoma patients who have completed primary treatment will develop osteosarcoma recurrence. (established) (no timestamp yet)
- About 95% of osteosarcoma samples examined express Src or have evidence of downstream activation of this pathway. (research) (no timestamp yet)
- Subjects with recurrent osteosarcoma localized to lung who had complete surgical removal of all lung nodules were randomized within six weeks after complete surgical resection. (recommendation) (no timestamp yet)
- Saracatinib was administered at a dose of 175 mg orally, once daily, for up to thirteen 28-day cycles. (recommendation) (no timestamp yet)
- Thirty-seven subjects were included in the analyses; 18 subjects were randomized to receive saracatinib and 19 to receive placebo. (research) (no timestamp yet)
- Intent-to-treat analysis demonstrated a median PFS of 19.4 months in the saracatinib treatment group and 8.6 months in the placebo treatment group (p=0.47). (research) (no timestamp yet)
- Median OS was not reached in either arm. (research) (no timestamp yet)
- Saracatinib was well tolerated in this patient population. (research) (no timestamp yet)
- There was no apparent impact of saracatinib in this double-blinded, placebo-controlled trial. (research) (no timestamp yet)
- There are no known effective medical treatments for refractory MPNST. (established) (no timestamp yet)
- Inactivation of the NF1 tumor suppressor in MPNST results in upregulation of mTOR signaling and angiogenesis, which contributes to disease progression. (established) (no timestamp yet)
- Everolimus was administered at 10 mg PO once daily in combination with bevacizumab 10 mg/kg IV every 2 weeks. (recommendation) (no timestamp yet)
- Clinical benefit rate was defined as complete response, partial response, or stable disease for at least 4 months. (established) (no timestamp yet)
- Patients 18 years or older with chemotherapy refractory sporadic or NF1 MPNST were eligible for enrollment. (recommendation) (no timestamp yet)
- Tumor response was assessed after every 2 cycles using the WHO criteria. (recommendation) (no timestamp yet)
- The study used a two-stage design targeting a 25% clinical benefit rate, requiring at least 1 of 15 patients in stage 1 to respond for expansion and at least 4 of 25 patients to have clinical benefit for the combination to be considered active. (established) (no timestamp yet)
- Twenty-five patients enrolled, including 17 with NF1 and 8 with sporadic MPNST. (research) (no timestamp yet)
- One of 15 patients in stage 1 had clinical benefit. (research) (no timestamp yet)
- Two of 10 additional patients enrolled in stage 2 had clinical benefit. (research) (no timestamp yet)
- The median number of completed cycles was 3, with a range of 1 to 16 cycles. (research) (no timestamp yet)
- The clinical benefit rate was 12% (3 of 25 patients). (research) (no timestamp yet)
- The combination of everolimus and bevacizumab did not reach the study's target response rate and is not considered active in refractory MPNST. (research) (no timestamp yet)
- Constitutively active RAS-GTP and increased MAPK signaling are important in tumorigenesis in neurofibromatosis type 1 and malignant peripheral nerve sheath tumors. (established) (no timestamp yet)
- Dual specificity phosphatases are negative regulators of MAPK signaling that dephosphorylate p38, JNK, and ERK. (established) (no timestamp yet)
- Targeted inhibition of DUSP1 and DUSP6 suppresses malignant peripheral nerve sheath tumor growth via JNK. (research) (no timestamp yet)
- CIC-rearranged sarcomas rarely occur in visceral organs including the kidney. (established) (no timestamp yet)
- The most common fusion partner with CIC is the DUX4 gene, but variant fusion partners have also been reported. (established) (no timestamp yet)
- All four cases of primary renal CIC-rearranged sarcoma occurred in females, with an age range of 13 to 82 years. (research) (no timestamp yet)
- There was a tendency for development of metastatic disease predominantly to the lungs and poor disease outcome despite different treatment strategies. (research) (no timestamp yet)
- Histologically, variable round cell (20% to 100%), spindle cell (0% to 80%), and rhabdoid morphologies (0% to 20%) were seen. (research) (no timestamp yet)
- Diffuse WT1 nuclear labeling (2 to 3+, approximately 90%) was present in 1 case, with cytoplasmic staining in the others (3+, 40% to 75%). (research) (no timestamp yet)
- CD99 was focally positive in all 4 cases (≤10%). (research) (no timestamp yet)
- One case each was diffusely positive for c-myc (2 to 3+, approximately 90%) and ETV4 (3+, approximately 90%). (research) (no timestamp yet)
- One case was focally positive for c-myc (2+, approximately 5%) and calretinin (2+, approximately 5%). (research) (no timestamp yet)
- All cases were negative for cytokeratin and NKX2.2. (research) (no timestamp yet)
- CIC rearrangement by fluorescence in situ hybridization was present in the 3 cases tested. (research) (no timestamp yet)
- Comprehensive genomic profiling of 3 cases revealed a CIC-DUX4 fusion in 2 cases and 1 CIC-NUTM1 fusion. (research) (no timestamp yet)
- All 4 CIC-rearranged renal sarcomas had low mutation burden. (research) (no timestamp yet)
- Except for HLA-A and MLL mutations, the tumors lacked genomic alterations in other oncogenic drivers. (research) (no timestamp yet)
- Biopsies of 72 patients with a variety of histiocytoses underwent comprehensive genomic profiling with targeted DNA and RNA sequencing. (research) (no timestamp yet)
- Fifteen patients (21%) carried the known BRAF V600E mutation. (research) (no timestamp yet)
- Eleven patients (15%) carried various mutations in MAP2K1, which induce constitutive activation of extracellular signal-regulated kinase (ERK) and were sensitive to inhibitors of mitogen-activated protein kinase kinase (MEK). (research) (no timestamp yet)
- Four LCH patients had an uncommon in-frame deletion in BRAF (N486_P490del or N486_T491>K), resulting in constitutive activation of ERK with resistance to V600E-specific inhibitors. (research) (no timestamp yet)
- Recurring ALK rearrangements were identified in histiocytoses. (research) (no timestamp yet)
- Patients with aggressive multisystem LCH experienced dramatic and sustained responses to monotherapy with either dabrafenib or trametinib. (research) (no timestamp yet)
- Comprehensive genomic profiling should be regularly applied to histiocytic disorders at diagnosis. (recommendation) (no timestamp yet)
- Comprehensive genomic profiling can positively impact clinical care in histiocytic disorders. (recommendation) (no timestamp yet)
- Zoledronic acid is a third-generation bisphosphonate used to reduce pain and skeletal events in patients with bone metastases from various malignancies. (established) (no timestamp yet)
- Pre-clinical studies indicate that zoledronic acid inhibits osteosarcoma through direct anti-proliferative effects, immune activation and anti-angiogenic activity. (research) (no timestamp yet)
- Expression of PAX3-FOXO1 in cooperation with SV40 Large-T antigen in murine C3H10T1/2 fibroblasts led to robust malignant transformation. (research) (no timestamp yet)
- 2D-DIGE analysis of cell lysates identified 93 protein spots that differed in abundance between PAX3-FOXO1 plus Large-T expressing cells versus Large-T alone. (research) (no timestamp yet)
- MALDI-TOF mass spectrometry analysis of the 93 differential spots identified 37 nonredundant proteins. (research) (no timestamp yet)
- 2D-DIGE analysis of conditioned cell culture media identified 29 spots in PAX3-FOXO1 plus Large-T cells, corresponding to 11 nonredundant secreted proteins. (research) (no timestamp yet)
- A substantial number of proteins with potential roles in tumorigenesis and myogenesis were detected, most of which have not been identified in previous wide-scale expression studies of rhabdomyosarcoma experimental models or tumors. (research) (no timestamp yet)
- Rhabdomyosarcoma is a family of soft tissue tumors associated with the skeletal muscle lineage and generally occurs in the pediatric population. (established) (no timestamp yet)
- Two histopathologic subtypes of rhabdomyosarcoma are embryonal (ERMS) and alveolar (ARMS), which are associated with distinct clinical characteristics and genetic alterations. (established) (no timestamp yet)
- Alveolar rhabdomyosarcoma is associated with 2;13 or 1;13 chromosomal translocations, which generate PAX3-FKHR and PAX7-FKHR fusion products, respectively. (research) (no timestamp yet)
- PAX3-FKHR and PAX7-FKHR translocations result in altered expression, function, and subcellular localization of the fusion products relative to wild-type proteins. (research) (no timestamp yet)
- PAX-FKHR fusion products contribute to oncogenic behavior by modifying growth, differentiation, and apoptosis pathways. (research) (no timestamp yet)
- Most embryonal rhabdomyosarcoma cases have allelic loss at chromosome 11p15.5. (research) (no timestamp yet)
- Chromosome fragment transfer studies demonstrated that the 11p15.5 region represses tumor cell growth, suggesting the presence of tumor suppressor gene(s) in this region. (research) (no timestamp yet)
- In both embryonal and alveolar rhabdomyosarcoma, there is evidence of collaborating alterations that affect common targets, such as the p53 and RB pathways. (research) (no timestamp yet)
- Amplification of genes such as MDM2 and CDK4 occurs frequently in alveolar rhabdomyosarcoma but only rarely in embryonal rhabdomyosarcoma. (research) (no timestamp yet)
- The striking cytogenetic and molecular differences between alveolar and embryonal rhabdomyosarcoma indicate distinct pathogenic mechanisms despite similarities in downstream targets. (research) (no timestamp yet)
- Rhabdomyosarcoma in patients with recurrent and metastatic disease have no successful treatment. (established) (no timestamp yet)
- Some embryonal rhabdomyosarcoma but not other sub-types are driven by sonic hedgehog signaling pathway. (established) (no timestamp yet)
- Smoothened inhibitors are not highly effective in animals for treating rhabdomyosarcoma. (research) (no timestamp yet)
- GLI1 and/or GLI2 are over-expressed in the majority of rhabdomyosarcoma cells. (research) (no timestamp yet)
- GANT-61 dampens the proliferation of both embryonal and alveolar rhabdomyosarcoma cells-derived xenograft tumors. (research) (no timestamp yet)
- About 50% tumor growth inhibition occurs in mice receiving GANT-61 treatment compared to vehicle-treated control. (research) (no timestamp yet)
- GANT-61 proliferation inhibition is associated with slowing of cell cycle progression mediated by reduced expression of cyclins D1/2/3 and E and concomitant induction of p21. (research) (no timestamp yet)
- GANT-61 reduces expression of GLI1/2 in rhabdomyosarcoma cells. (research) (no timestamp yet)
- GANT-61 significantly diminishes AKT/mTOR signaling in rhabdomyosarcoma. (research) (no timestamp yet)
- The therapeutic action of GANT-61 is significantly augmented when combined with temsirolimus or vincristine. (research) (no timestamp yet)
- Reduced expression of proteins driving epithelial mesenchymal transition characterizes residual tumors after GANT-61 treatment. (research) (no timestamp yet)
- Rhabdomyosarcomas represent the most common childhood soft-tissue sarcoma. (established) (no timestamp yet)
- Patients with metastatic or relapsed rhabdomyosarcoma face a grim prognosis despite improvements in outcomes for low and intermediate risk patients. (established) (no timestamp yet)
- New chemotherapeutic agents or combinations of chemotherapies have largely failed to improve outcomes in rhabdomyosarcoma. (established) (no timestamp yet)
- The PI3K/AKT/mTOR pathway has been found to be a potentially attractive target in rhabdomyosarcoma therapy. (established) (no timestamp yet)
- Rapamycin abrogates growth of rhabdomyosarcoma development in a xenograft mouse model. (research) (no timestamp yet)
- More than 95% inhibition in tumor growth was observed in mice receiving parenteral administration of rapamycin compared to vehicle-treated controls. (research) (no timestamp yet)
- Residual tumors in rapamycin-treated mice showed significant reduction in the expression of biomarkers indicative of proliferation and tumor invasiveness. (research) (no timestamp yet)
- Tumors in rapamycin-treated mice showed enhanced apoptosis. (research) (no timestamp yet)
- Rapamycin diminished rhabdomyosarcoma tumor growth through simultaneous inhibition of mTOR and hedgehog pathways. (research) (no timestamp yet)
- Rhabdomyosarcoma is comprised of two major histological subtypes: embryonal (E-RMS) and alveolar (A-RMS). (established) (no timestamp yet)
- Subsets of each rhabdomyosarcoma subtype demonstrate resistance to multimodal therapy leading to treatment failure. (established) (no timestamp yet)
- CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant. (research) (no timestamp yet)
- CD133-positive rhabdomyosarcoma cells are sensitive to mutant herpes simplex virus. (research) (no timestamp yet)
- Rhabdomyosarcoma is a common soft-tissue sarcoma of childhood in need of more effective therapeutic options. (established) (no timestamp yet)
- The expression of p53 in rhabdomyosarcoma is heterogeneous such that some tumors are wild-type whereas others are p53 mutant. (established) (no timestamp yet)
- CP-31398 blocks the growth of rhabdomyosarcoma cells that have either wild-type or mutant p53 status. (research) (no timestamp yet)
- In wild-type A204 cells, CP-31398 increased the expression of p53 and its downstream transcriptional targets, p21 and mdm2. (research) (no timestamp yet)
- CP-31398 enhanced the expression of apoptosis-related proteins and reduced proliferation biomarkers in wild-type A204 cells. (research) (no timestamp yet)
- Flow profiling of CP-31398-treated cells indicated an enhancement in sub-G0 and G1 populations. (research) (no timestamp yet)
- CP-31398 inhibited proliferation in a manner associated with co-induction of SOX9 and p21. (research) (no timestamp yet)
- Apoptosis induced by CP-31398 occurred with translocation of p53 to mitochondria, leading to altered mitochondrial membrane potential, cytochrome c release, and reactive oxygen species release. (research) (no timestamp yet)
- CP-31398 decreased the growth of tumor xenografts composed of wild-type or mutant p53 tumor cells in vivo. (research) (no timestamp yet)
- CP-31398 increased tumor-free host survival in xenograft models. (research) (no timestamp yet)
- The ability of CP-31398 to modulate wild-type and mutant p53 results in the inhibition of rhabdomyosarcoma growth and invasiveness. (research) (no timestamp yet)
- Overall survival of patients with osteosarcoma has remained constant with no substantial improvement in the past 15 years. (established) (no timestamp yet)
- Advances in imaging have had a substantial impact on surgical planning and staging in osteosarcoma. (established) (no timestamp yet)
- Ewing sarcoma and peripheral primitive neuroectodermal tumor share clinicopathologic and molecular genetic features, including characteristic chromosomal translocation resulting in fusion of the EWS gene on 22q12 to either the FLI1 gene on 11q24 or other Ets family transcription factor genes such as the ERG gene on 21q22. (established) (no timestamp yet)
- The characteristic EWS gene translocations found in Ewing sarcoma are not found in central primitive neuroectodermal tumors such as medulloblastoma and supratentorial PNET. (established) (no timestamp yet)
- Ewing sarcoma has only rarely been noted to primarily involve the central nervous system as extraosseous Ewing sarcoma (CNS-EES). (established) (no timestamp yet)
- Positive membranous immunostaining for CD99 and demonstration of EWS-FLI1 fusion by fluorescence in situ hybridization studies confirm the diagnosis of CNS-EES. (recommendation) (no timestamp yet)
- CNS-EES may look identical to central primitive neuroectodermal tumors but differs in histogenesis, molecular characteristics, and clinical behavior. (established) (no timestamp yet)
- Demonstration of characteristic translocations by molecular studies differentiates CNS-EES from cPNET and helps clinicians make informed decisions regarding therapy. (recommendation) (no timestamp yet)

---
Educational content from recorded physician discussions — not medical advice. Cite the canonical URL or the ?t= deep link. Policy: https://library.globalcastmd.com/ai
